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tatin treatment results in a reduction of cardiovascular (CV)
events during the ﬁrst year of treatment. This study was con-
ducted to estimate the early clinical and economic consequences
of initiating statin therapy with atorvastatin vs. simvastatin
from a Canadian societal perspective. METHODS: A cost-
consequence model was developed to estimate CV events and
costs over the ﬁrst 2 years of treatment associated with initiating
atorvastatin or simvastatin in a hypothetical cohort of 100,000
patients. Four groups of new users were considered, including
patients with: 1) diabetes; 2) multiple CV risk factors; 3) coro-
nary heart disease; and 4) acute coronary syndrome. RCT data
were used to estimate the CV event rate for each statin. CV
events included myocardial infarction, stroke, and revasculariza-
tion procedures. Corresponding direct costs (i.e., health care
utilisation, drug) were obtained from the Ontario Drug Beneﬁt
and Ontario Case Costing Initiative. Estimates of indirect costs
(loss of productivity) were obtained from Statistics Canada. All
costs were expressed in 2007 Canadian dollars. Multivariate
(Monte Carlo simulation) and univariate sensitivity analyses
were conducted on model assumptions. RESULTS: Within two
years of treatment initiation, the use of atorvastatin is predicted
to prevent 1648 CV events (95% CI: 1343–1956) per 100,000
new patients compared with simvastatin. Similarly, the cost of
CV events was reduced by $50.8 million (95% CI: $41.9–$59.8).
The incremental cost associated with atorvastatin treatment
was $31.3 million. This resulted in a net saving of $19.5 million
(95% CI: $10.7–$28.7). Savings were also observed across all
four groups considered. Results were sensitive to assumptions
regarding simvastatin efﬁcacy and levels of persistence. CON-
CLUSION: Based on this model, atorvastatin use is predicted to
result in cost savings to the Canadian society over simvastatin use
within 2 years of therapy initiation.
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OBJECTIVE: Clinical guidelines recommend frequent follow-up
visits for patients initiating antidepressant treatment in order to
provide patient support, adjust dosage, and monitor side effects
and clinical response. We examined the frequency of follow-up
visits and factors associated with having guideline concordant
care during the acute phase of antidepressant treatment.
METHODS: Medical and prescription claims from a large
national health plan afﬁliated with i3 Innovus were analyzed
with a retrospective cohort design. Adults newly diagnosed with
major depressive disorder (n = 4447) from July 2000 to Decem-
ber 2002 who started a course of antidepressant treatment were
included. Follow-up visits during the ﬁrst three months after the
index prescription were counted, and patients were classiﬁed as
receiving guideline-concordant care if they had at least three
visits. Logistic regression was used to explore the predictors for
having the minimum number of recommended follow-up visits.
RESULTS: The mean number of follow-up visits during acute
phase treatment was 2.68. Only 43.4% of patients received
guideline-recommended level of follow-up care. In regression
analysis, an initial prescription from a psychiatrist was the stron-
gest predictor (OR = 2.66, 95% CI = 2.30–3.07). Receiving
psychotherapy, having comorbid anxiety, and having a lower
copayment was also positively associated with the probability of
guideline-recommended follow-up care (P < 0.05). CONCLU-
SION: Routine care for antidepressant management falls short of
guideline recommendations, especially in primary care. Modiﬁ-
able factors such as provider of care and copayments appear to
inﬂuence the likelihood of receiving guideline-concordant care.
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OBJECTIVE: Estimate the impact of adhering to lipid treatment
guidelines [National Cholesterol Education Program’s Third
Report on Detection, Evaluation, and Treatment of High Blood
Cholesterol and Adult Treatment Panel’s (NCEP-ATP III)] on
cardiovascular disease (CVD) events and associated costs in a
managed care population. METHODS: A retrospective analysis
was conducted using the HealthCore Integrated Research
Database on patients with laboratory values on low-density
lipoprotein-cholesterol (LDL-C), high-density lipoprotein-
cholesterol (HDL-C), & triglycerides (TG) between Janaury 1,
2003-December 31, 2005 [index date], no lipid therapy
6-months pre-index date, and minimum 12 months health plan
eligibility pre- and post-index date. Baseline lipid levels and the
ﬁrst post-index follow-up lipid panel (goal attainment), and risk
stratiﬁcation per NCEP-ATP III guidelines were used to catego-
rize patients as appropriately (AM) or inappropriately managed
(IAM). End points included counts of CVD events (ischemic
heart disease, peripheral vascular disease, stroke and related
occurrences and interventions) through Poisson regression and
associated annual total CVD-attributable costs ($CV) during
follow-up (multivariate generalized linear model regression)
between groups after controlling for baseline clinical and demo-
graphic differences. RESULTS: A total of 8176 patients (3493
AM; 4683 IAM) were identiﬁed. AM patients were signiﬁcantly
older [mean (SD) ages of 51.4 (9.1) vs. 50.0 (9.6); p < 0.01] and
comprised of fewer males (43.2% vs. 56.2%; p < 0.01). Baseline
Deyo-Charlson comorbidity scores were signiﬁcantly lower
among AM patients (0.20  0.44 vs. 0.32  0.56; p < 0.01).
During follow-up, AM patients had a 10% reduction in the
annual rate of CV events [Annual Event Rate (AER) = 0.90; 95%
CI, 0.86–0.93] as compared to IAM patients. A 12% reduction
in annual total $CV [Estimate: 0.88 (95% CI, 0.80–0.98) [$696
vs. $788; p = 0.02] was observed among AM patients versus
IAM patients. CONCLUSION: Comprehensive dyslipidemia
management reﬂecting clinical guideline treatment recommenda-
tions was associated with reductions in CVD events and $CV in
this managed care population.
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OBJECTIVE: There is much controversy about the value of new
medications and the substantial spending on R&D associated
with new treatments. The current study aimed at evaluating the
impact of drug innovation on longevity in three important
disease areas using patient-level data. METHODS: An analysis
of health claims from Quebec’s provincial health plan data
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between 1997 and 2006 was conducted. Elderly patients with
continuous health plan coverage,  drug prescription per calen-
dar year, and  diagnosis for 1) asthma; 2) cancer; or 3) cardio-
vascular disease (CVD) were selected. Drug vintage, deﬁned as
the ingredient’s earliest marketed date, was drawn from Health
Canada Drug Product Database. A multivariate analysis was
conducted to estimate the impact of drug vintage on patients’
probability of dying using time-varying Cox proportional hazard
model. The covariates used for adjustment in the regression
model were: demographics characteristics, guaranteed income
supplement (GIS) status, medical resources utilization, concomi-
tant drug utilization, and comorbidities. RESULTS: A total of
6912, 12,341, and 29,394 elderly subjects formed the asthma,
cancer, and CVD study populations, respectively, of which 1220
(18%), 3479 (28%), and 6043 (21%) died during the observa-
tion period. Overall, mean age was 68 years; 49% of subjects
were women. After controlling for confounding factors, the use
of recent medications (i.e. Post-1990 ingredients) was consis-
tently associated with a signiﬁcant risk reduction of mortality
(hazard ratios <1.0, p < 0.0001 for all disease areas), relative to
older ingredients, suggesting that recent drug innovation had a
signiﬁcant beneﬁcial impact on longevity in patients with asthma,
cancer, or CVD. Other covariates associated with an increased
risk of mortality included age, gender, GIS beneﬁciaries, hospi-
talization, and number of comorbidities. CONCLUSION: This
analysis showed that drug innovation, in particular medications
launched after 1990, had a signiﬁcant beneﬁcial impact on lon-
gevity of elderly patients in three important disease areas.
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OBJECTIVE: Safety, efﬁcacy, and ﬁnancial concerns are impor-
tant considerations when evaluating the reasons for market
discontinuation of drugs. In this study, market discontinuation
of new chemical entities (NCEs) approved by the FDA in the
period 1980–2007 were analyzed according to therapeutic class,
regulatory changes, orphan drug status, and priority review.
METHODS: Data was derived from the FDA, Micromedex and
Medline. A drug was considered discontinued if deleted from
the FDA’s Orange book. Withdrawals of approval were also
included in the study. Descriptive statistics and chi-square tests
were performed. RESULTS: A total of 703 NCEs were approved
during the study period. In December 31, 2007, 71.8% NCEs
remained in the market; 14.9% were discontinued; 5.4% NCES
had the brand discontinued, but the generic was available; 7.0%
had changes in route, dosage form or strength; and 0.9% were
over-the-counter drugs. Safety was the primary reason for with-
drawal of 30 (4.3%) NCEs; 14 (2.0%) NCEs had Federal Reg-
ister determination for not being discontinued for safety or
efﬁcacy reasons; and 61 (8.7%) had no reasons stated by the
FDA. Compared to other classes antibiotics were more likely
(p < 0.05) to be discontinued. Analyses of priority review, orphan
drug status, and the sponsor company’s country (US or non-US)
with respect to market withdrawal were not signiﬁcant. Com-
parisons of pharmaceuticals withdrawn due to safety reasons
with therapeutic class and implementation of Prescription Drug
User Fee Act were also not signiﬁcant. CONCLUSION: One in
seven NCEs approved during the study period were discontinued
from the market. A small percentage of drugs were discontinued
due to safety or ﬁnancial reasons. An ongoing evaluation of
NCEs in the market place is important to determine which prod-
ucts provide optimal beneﬁts in terms of efﬁcacy, safety, and
value compared to other products overall and other products
within the same therapeutic class.
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OBJECTIVE: The U.S. Medicare drug beneﬁt (Part D) was
implemented in January 2006 to reduce cost-related underuse of
medications, experienced by 25% of older patients in the US.
This study evaluated the impact of Part D on medication use
patterns and cost-savings for subsequent medical services.
METHODS: We collected all claims of 20,645 members from a
large Medicare managed care plan between January 1, 2005 and
December 31, 2006. We used a time series and comparison group
design to measure the changes in outcomes before and after Part
D. Intervention group included members who had no drug cov-
erage or quarterly caps in drug spending and whose coverage
became more generous after Part D. The comparison group had
no limits on drug spending before and after Part D. We estimated
the impact of Part D on 1) out-of-pocket pharmacy spending and
non-drug medical spending using generalized linear models;
2) number of monthly drug scripts, medication adherence, and
counts of hospitalization and ED visits using Poisson regressions;
and 3) adherence for antihypertensive, lipid-lowering, anti-
diabetic, and antipsychotic agents using generalized-estimating-
equation models. RESULTS: Part D reduced out-of-pocket
expenditures by 20%–50% depending on members’ drug limits.
Part D increased number of monthly drug scripts by 0.5, among
members without drug coverage who prescribed 3 scripts per
month and members with quarterly $150 cap who prescribed
about 3.5 monthly scripts in 2005. We did not ﬁnd improve-
ments on medication adherence for selected drug classes. We
found total medical and inpatient spending reduced by 10% (not
statistically signiﬁcant) for members who had a previous $625
quarterly cap. We did not ﬁnd any cost offsets for members with
other drug limits. CONCLUSION: Part D decreased out-of-
pocket pharmacy expenditures and increased demand for drugs
but did not induce savings from subsequent medical services.
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OBJECTIVE: Since the implementation of Medicare Part D,
numerous anecdotal descriptions and a few small studies have
reported low reimbursements to community pharmacies. The
purpose of this study was to quantitatively assess the impact of
Medicare Part D on percent gross margin earned by independent
pharmacies in Texas using prescription claims data collected by a
pharmacy claims switching company for dual eligible beneﬁcia-
ries. METHODS: The study evaluated a total of 457,611 claims
for prescriptions dispensed in the fourth quarter of 2005
(n = 152,521) and the second and third quarters of 2006
(n = 305,090). The prescriptions were dispensed by 313 indepen-
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